No black box warning on record for Tenofovir Disoproxil Fumarate

As of the latest FDA labeling reviewed, Tenofovir Disoproxil Fumarate (TENOFOVIR DISOPROXIL FUMARATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tenofovir Disoproxil Fumarate medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine clearance before initiating treatment with tenofovir disoproxil fumarate tablets. In patients at risk for renal dysfunction, assess estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein before initiating treatment with

No black box warning on record for Tenofovir Disoproxil Fumarate

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine clearance before initiating treatment with tenofovir disoproxil fumarate tablets. In patients at risk for renal dysfunction, assess estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein before initiating treatment with

Tenofovir Disoproxil Fumarate Black Box Warning

No black box warning on record for Tenofovir Disoproxil Fumarate

Other warnings & precautions

Tenofovir Disoproxil Fumarate Black Box Warning

No black box warning on record for Tenofovir Disoproxil Fumarate

Other warnings & precautions